Lawler Mark, Banks Ian, Law Kate, Albreht Tit, Armand Jean-Pierre, Barbacid Mariano, Barzach Michèle, Bergh Jonas, Cameron David, Conte Pierfranco, de Braud Filippo, de Gramont Aimery, De Lorenzo Francesco, Diehl Volker, Diler Sarper, Erdem Sema, Geissler Jan, Gore-Booth Jola, Henning Geoffrey, Højgaard Liselotte, Horgan Denis, Jassem Jacek, Johnson Peter, Kaasa Stein, Kapitein Peter, Karjalainen Sakari, Kelly Joan, Kienesberger Anita, La Vecchia Carlo, Lacombe Denis, Lindahl Tomas, Löwenberg Bob, Luzzatto Lucio, Malby Rebecca, Mastris Ken, Meunier Françoise, Murphy Martin, Naredi Peter, Nurse Paul, Oliver Kathy, Pearce Jonathan, Pelouchov Jana, Piccart Martine, Pinedo Bob, Spurrier-Bernard Gilly, Sullivan Richard, Tabernero Josep, Van de Velde Cornelis, van Herk Bert, Vedsted Peter, Waldmann Anita, Weller David, Wilking Nils, Wilson Roger, Yared Wendy, Zielinski Christoph, Zur Hausen Harald, Le Chevalier Thierry, Johnston Patrick, Selby Peter
Queen's University Belfast,; European Cancer Concord.
European Cancer Concord,; European Men's Health Forum,; University of Leeds.
ESMO Open. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen-2016-000127. eCollection 2016.
In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative:The right of every European citizen to receive the most accurate information and to be proactively involved in his/her care.The right of every European citizen to optimal and timely access to a diagnosis and to appropriate specialised care, underpinned by research and innovation.The right of every European citizen to receive care in health systems that ensure the best possible cancer prevention, the earliest possible diagnosis of their cancer, improved outcomes, patient rehabilitation, best quality of life and affordable health care. The key aspects of working towards implementing the BoR are:Agree our high-level goal. The vision of 70% long-term survival for patients with cancer in 2035, promoting cancer prevention and cancer control and the associated progress in ensuring good patient experience and quality of life.Establish the major mechanisms to underpin its delivery. (1) The systematic and rigorous sharing of best practice between and across European cancer healthcare systems and (2) the active promotion of Research and Innovation focused on improving outcomes; (3) Improving access to new and established cancer care by sharing best practice in the development, approval, procurement and reimbursement of cancer diagnostic tests and treatments.Work with other organisations to bring into being a Europe based centre that will (1) systematically identify, evaluate and validate and disseminate best practice in cancer management for the different countries and regions and (2) promote Research and Innovation and its translation to maximise its impact to improve outcomes.
在欧洲癌症患者权利法案（BoR）的这一实施阶段，我们确认以下三项以患者为中心的原则，这些原则是该倡议的基础：
每位欧洲公民有权获得最准确的信息并积极参与自身护理。
每位欧洲公民有权在研究与创新的支持下，及时获得最佳的诊断和适当的专科护理。
每位欧洲公民有权在卫生系统中接受护理，这些系统要确保尽可能最佳的癌症预防、尽早诊断癌症、改善治疗效果、患者康复、最佳生活质量以及可负担的医疗保健。
商定我们的高层次目标。即到2035年癌症患者实现70%的长期生存率，促进癌症预防和控制，并在确保良好患者体验和生活质量方面取得相关进展。
建立支持其实施的主要机制。（1）欧洲癌症医疗系统之间及内部系统地、严格地分享最佳实践；（2）积极推动专注于改善治疗效果的研究与创新；（3）通过分享癌症诊断测试和治疗的开发、批准、采购和报销方面的最佳实践，改善获得新的和已有的癌症护理的机会。
与其他组织合作，成立一个总部位于欧洲的中心，该中心将（1）系统地识别、评估、验证和传播不同国家和地区癌症管理的最佳实践；（2）促进研究与创新及其转化，以最大限度地提高其影响，改善治疗效果。
